{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:31:29Z","timestamp":1768703489266,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ygyno.2014.04.039","type":"journal-article","created":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T08:17:54Z","timestamp":1398327474000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Oxaliplatin salvage for recurrent ovarian cancer: A single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity"],"prefix":"10.1016","volume":"134","author":[{"given":"Sarah E.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany L.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin K.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2014.04.039_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer Statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"3 Pt 2","key":"10.1016\/j.ygyno.2014.04.039_bb0010","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1006\/gyno.1994.1347","article-title":"Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials","volume":"55","author":"Thigpen","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.04.039_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2014.04.039_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr Oncol"},{"issue":"9375","key":"10.1016\/j.ygyno.2014.04.039_bb0030","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2014.04.039_bb0035","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ygyno.2006.09.023","article-title":"Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer","volume":"104","author":"Strauss","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.04.039_bb0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.04.039_bb0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Gynecologic Oncology Group","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.ygyno.2014.04.039_bb0050","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","article-title":"Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.04.039_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","article-title":"A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"122","author":"Coleman","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/j.ygyno.2014.04.039_bb0060","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2014.04.039_bb0065","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","article-title":"A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study","volume":"57","author":"Omura","year":"1986","journal-title":"Cancer"},{"issue":"40","key":"10.1016\/j.ygyno.2014.04.039_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study","volume":"7","author":"Omura","year":"1989","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2014.04.039_bb0075","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.1996.14.6.1895","article-title":"Carboplatin and paclitaxel in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group","volume":"14","author":"Bookman","year":"1996","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ygyno.2014.04.039_bb0080","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ygyno.2014.04.039_bb0085","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ygyno.2014.04.039_bb0090","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.04.039_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ygyno.2014.04.039_bb0100","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer \u2014 a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ygyno.2014.04.039_bb0105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase iii-study from the German CONKO-Study group","volume":"47","author":"Pelzer","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2014.04.039_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0027-5107(01)00141-5","article-title":"Mechanisms of resistance to cisplatin","volume":"478","author":"Kartalou","year":"2001","journal-title":"Mutat Res"},{"issue":"3","key":"10.1016\/j.ygyno.2014.04.039_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/187152810792231887","article-title":"Acute hypersensitivity reactions to chemotherapy agents: an overview","volume":"9","author":"Syrigou","year":"2010","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.ygyno.2014.04.039_bb0120","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met Based Drugs"},{"issue":"15","key":"10.1016\/j.ygyno.2014.04.039_bb0125","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO.2003.03.077","article-title":"Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group study","volume":"21","author":"Fracasso","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2014.04.039_bb0130","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","article-title":"Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer","volume":"7","author":"Chollet","year":"1996","journal-title":"Ann Oncol"},{"issue":"1B","key":"10.1016\/j.ygyno.2014.04.039_bb0135","first-page":"495","article-title":"Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)","volume":"28","author":"Kalykaki","year":"2008","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.ygyno.2014.04.039_bb0140","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/IGC.0b013e3181b62f38","article-title":"Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer","volume":"19","author":"Seliger","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2014.04.039_bb0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00404-008-0592-9","article-title":"Oxaliplatin\/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma","volume":"278","author":"Rosa","year":"2008","journal-title":"Arch Gynecol Obstet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581400897X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581400897X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T21:25:04Z","timestamp":1565385904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581400897X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S009082581400897X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.039","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxaliplatin salvage for recurrent ovarian cancer: A single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}